237 related articles for article (PubMed ID: 22127466)
1. Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI.
Kaneko A; Kida D; Saito K; Tsukamoto M; Sato T
Rheumatol Int; 2012 Nov; 32(11):3631-7. PubMed ID: 22127466
[TBL] [Abstract][Full Text] [Related]
2. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
Funahashi K; Koyano S; Miura T; Hagiwara T; Okuda K; Matsubara T
Mod Rheumatol; 2009; 19(5):507-12. PubMed ID: 19609487
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
Kaneshiro S; Ebina K; Hirao M; Tsuboi H; Nishikawa M; Nampei A; Nagayama Y; Takahi K; Noguchi T; Owaki H; Hashimoto J; Yoshikawa H
Mod Rheumatol; 2017 Jan; 27(1):42-49. PubMed ID: 27181115
[TBL] [Abstract][Full Text] [Related]
6. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients.
Morris NT; Brook J; Ben-Artzi A; Martin W; Kermani TA; Avedikian-Tatosyan L; Karpouzas G; Nagam H; Navarro G; Choi S; Taylor MB; Elashoff D; Kaeley GS; Ranganath VK
Clin Rheumatol; 2021 Dec; 40(12):5055-5065. PubMed ID: 34269927
[TBL] [Abstract][Full Text] [Related]
7. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
8. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Yamasaki S; Nakamura H; Ueki Y; Migita K; Mizokami A; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2011 Aug; 21(4):365-9. PubMed ID: 21229375
[TBL] [Abstract][Full Text] [Related]
9. Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
Kawashiri SY; Nishino A; Suzuki T; Nakashima Y; Horai Y; Ueki Y; Aramaki T; Fujikawa K; Nakashima M; Okada A; Migita K; Mizokami A; Matsuoka N; Mine M; Sakito S; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aoyagi K; Eguchi K; Kawakami A
Clin Exp Rheumatol; 2016; 34(5):808-812. PubMed ID: 27384149
[TBL] [Abstract][Full Text] [Related]
10. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
12. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
[TBL] [Abstract][Full Text] [Related]
13. Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T; Yabe Y; Kaneko A; Hirano Y; Ishikawa H; Hayashi M; Miyake H; Takagi H; Kato T; Terabe K; Wanatabe T; Tsuchiya H; Kida D; Shioura T; Funahashi K; Kato D; Matsubara H; Takahashi N; Hattori Y; Asai N; Ishiguro N
Mod Rheumatol; 2013 Sep; 23(5):977-85. PubMed ID: 23099471
[TBL] [Abstract][Full Text] [Related]
14. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
Mod Rheumatol; 2014 Jan; 24(1):17-25. PubMed ID: 24261754
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
16. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.
Shafran IH; Alasti F; Smolen JS; Aletaha D
Ann Rheum Dis; 2020 Jul; 79(7):874-882. PubMed ID: 32371387
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study.
Nishimoto N; Takagi N
Mod Rheumatol; 2010 Dec; 20(6):539-47. PubMed ID: 20617358
[TBL] [Abstract][Full Text] [Related]
18. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
Dhaon P; Das SK; Srivastava R; Dhakad U
Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
[TBL] [Abstract][Full Text] [Related]
19. Suppression of active, but not total MMP-3, is associated with treatment response in a phase III clinical study of rheumatoid arthritis.
Siebuhr AS; Kjelgaard-Petersen CF; Sun S; Byrjalsen I; Christiansen C; Karsdal MA; Bay-Jensen AC
Clin Exp Rheumatol; 2018; 36(1):94-101. PubMed ID: 28850021
[TBL] [Abstract][Full Text] [Related]
20. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.
Kojima T; Yabe Y; Kaneko A; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Asai S; Hirabara S; Asai N; Hirano Y; Hayashi M; Miyake H; Kojima M; Ishiguro N
Rheumatology (Oxford); 2015 Jan; 54(1):113-20. PubMed ID: 25102861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
